These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 21216118)
81. Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon. Barut S; Yuksek J; Sezer E; Gunal O; Koseoglu D J Dermatol; 2011 May; 38(5):479-81. PubMed ID: 21352322 [TBL] [Abstract][Full Text] [Related]
82. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid. Mao Q; Zhang HY; You JP; Zhang XQ Virol J; 2012 Jul; 9():136. PubMed ID: 22828242 [TBL] [Abstract][Full Text] [Related]
83. Acute pancreatitis during pegylated interferon therapy in a patient with chronic hepatitis B. Vignon RK; Seddik H; Rouibaa F; En-Nouali H; Kabbaj N; Benkirane A J Gastrointestin Liver Dis; 2009 Dec; 18(4):512. PubMed ID: 20076835 [No Abstract] [Full Text] [Related]
84. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b. Neff BA; Voss SG; Carlson ML; O'Brien EK; Butterfield JH Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784 [TBL] [Abstract][Full Text] [Related]
85. Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha. Liu Y; Zheng Y; Lin X; Cao Z; Lu J; Ma L; Ren S; Zheng S; Hu Z; Xu B; Chen X BMC Endocr Disord; 2023 May; 23(1):115. PubMed ID: 37217910 [TBL] [Abstract][Full Text] [Related]
86. Use of pegylated interferon in hypereosinophilic syndrome. Butterfield JH; Weiler CR Leuk Res; 2012 Feb; 36(2):192-7. PubMed ID: 22118911 [TBL] [Abstract][Full Text] [Related]
87. Effect of Interferon-α and Combined Interferon-α with Lamivudine Treatment on Anthropometric Measurements in Children with Chronic Hepatitis B. Urganci N; Kalyoncu D; Erdem Eralp E Ann Nutr Metab; 2017; 71(1-2):8-9. PubMed ID: 28624823 [No Abstract] [Full Text] [Related]
88. Superficial venous thrombophlebitis associated with pegylated interferon alpha-2a treatment in a patient with chronic hepatitis B. Kalafateli M; Triantos C; Kakkos SK; Mougiou A; Labropoulou-Karatza C J Gastrointestin Liver Dis; 2012 Sep; 21(3):328-9. PubMed ID: 23012682 [No Abstract] [Full Text] [Related]
89. Membranous nephropathy induced by pegylated interferon alpha-2a therapy for chronic viral hepatitis B. Tsai MS; Chen JH; Fang YW; Yang AH; Chang CH Clin Nephrol; 2012 Jun; 77(6):496-500. PubMed ID: 22595393 [TBL] [Abstract][Full Text] [Related]
90. The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Görür K; Kandemir O; Unal M; Ozcan C Auris Nasus Larynx; 2003 Feb; 30(1):41-4. PubMed ID: 12589849 [TBL] [Abstract][Full Text] [Related]
91. Pityriasis rosea in a hepatitis B-positive patient treated with pegylated interferon α2a: report of a case and review of the literature. Drago F; Javor S; Bruzzone L; Drago F; Parodi A; Picciotto A Dermatology; 2014; 228(1):10-3. PubMed ID: 24335203 [TBL] [Abstract][Full Text] [Related]
92. Severe agranulocytosis as a rare side effect of pegylated interferon therapy for chronic hepatitis B. Zizer E; Bommer M; Barth T; Dikopoulos N Z Gastroenterol; 2011 May; 49(5):596-8. PubMed ID: 21557170 [TBL] [Abstract][Full Text] [Related]
93. Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. Kartal ED; Alpat SN; Ozgunes I; Usluer G Adv Ther; 2007; 24(5):963-71. PubMed ID: 18029321 [TBL] [Abstract][Full Text] [Related]
94. [A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon α-2a in a patient with chronic hepatitis B virus infection]. Naito H; Takeda I; Segawa A; Tsuge M; Maruyama H; Matsumoto M Rinsho Shinkeigaku; 2016 Oct; 56(10):672-677. PubMed ID: 27680223 [TBL] [Abstract][Full Text] [Related]
95. Facial hyperpigmentation during pegylated interferon alpha therapy for chronic hepatitis B infection. Dag MS; Aydinli M; Kazanci U; Kadayifci A Acta Gastroenterol Belg; 2011 Mar; 74(1):103-4. PubMed ID: 21563666 [No Abstract] [Full Text] [Related]
96. Pegylated-interferon alpha (PEG-IFNα)-induced interstitial lung disease in a patient with chronic hepatitis B: A case report and literature review. Shi M; Wang S; Ren Y; Zhao L; Liu M; Yang L; Yang T Int J Clin Pharmacol Ther; 2024 Aug; 62(8):386-394. PubMed ID: 38699975 [TBL] [Abstract][Full Text] [Related]
97. Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. Milkiewicz P; Yim C; Pache I; Heathcote J Can J Gastroenterol; 2005 Nov; 19(11):677-8. PubMed ID: 16292363 [TBL] [Abstract][Full Text] [Related]
98. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Ianotto JC; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; De Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Schoenwald M; Andreoli A; Abgrall JF; Kiladjian JJ Br J Haematol; 2013 Sep; 162(6):783-91. PubMed ID: 23848933 [TBL] [Abstract][Full Text] [Related]
99. A case of hyperthyroidy developing in "pegylated-interferon" therapy. Aslan M; Nazligul Y; Aksoy N; Yilmaz N Dig Dis Sci; 2007 May; 52(5):1194-6. PubMed ID: 17372828 [No Abstract] [Full Text] [Related]
100. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature. Lawson BO; Khong HT Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]